1. Home
  2. Directory
  3. Louisiana
  4. New Orleans
  5. Urology
  6. NPI Profile
  7. Prescriptions 1942267521

DR. STEPHEN F. BARDOT MD
Prescription History 1942267521
Urology in New Orleans, LA

NPI Status: Active since April 27, 2006

Contact Information

1514 JEFFERSON HWY
NEW ORLEANS, LA
ZIP 70121
Phone: (504) 842-4000

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. STEPHEN F. BARDOT MD, an active Urology specialist practicing in New Orleans, LA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 192 documented patient claims. Among these therapy options, the most frequently utilized medication is Tamsulosin Hcl, which accounts for 81 claims alone.

Medication Index

C
D
F
T
No matching medications currently found on file.

Ciprofloxacin Hcl

Generic Formulation: Ciprofloxacin HclSpecialty: Urology
Provider Metrics Summary
Total Claims 55
30-Day Fills 57.0
Days Supply 168
LA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.1
Peer Average Days Supply318
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 71.9% higher than the standard regional baseline profile for LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $61.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$1.12

State Avg Cost Per Claim

$7.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum antimicrobial carboxyfluoroquinoline.

Therapeutic Applications

This medication is used to treat eye infections. Ciprofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Dutasteride

Generic Formulation: DutasterideSpecialty: Urology
Provider Metrics Summary
Total Claims 21
30-Day Fills 61.0
Days Supply 1,830
LA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills68.5
Peer Average Days Supply2,035
Conservative Utilization

This provider writes prescriptions for this formulation 38.2% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $838.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.95

State Avg Cost Per Claim

$38.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.

Therapeutic Applications

This medication is used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It works by reducing the size of the enlarged prostate. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate frequently or urgently (including during the middle of the night). It may also reduce the need for surgery to treat BPH. Dutasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. This medication should not be used by women or children.

Finasteride

Generic Formulation: FinasterideSpecialty: Urology
Provider Metrics Summary
Total Claims 22
30-Day Fills 66.0
Days Supply 1,980
LA State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills133.1
Peer Average Days Supply3,941
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.9% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $350.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.93

State Avg Cost Per Claim

$14.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.

Therapeutic Applications

Finasteride is used to shrink an enlarged prostate (benign prostatic hyperplasia or BPH) in adult men. It may be used alone or taken in combination with other medications to reduce symptoms of BPH and may also reduce the need for surgery. Finasteride may improve symptoms of BPH and provide benefits such as decreased urge to urinate, better urine flow with less straining, less of a feeling that the bladder is not completely emptied, and decreased nighttime urination. This medication works by decreasing the amount of a natural body hormone (DHT) that causes growth of the prostate. Finasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. Women and children should not use this medication.

Tadalafil

Generic Formulation: TadalafilSpecialty: Urology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
LA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills37.6
Peer Average Days Supply1,122
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.1% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $205.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.82

State Avg Cost Per Claim

$523.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carboline derivative and PHOSPHODIESTERASE 5 INHIBITOR that is used primarily to treat ERECTILE DYSFUNCTION; BENIGN PROSTATIC HYPERPLASIA and PRIMARY PULMONARY HYPERTENSION.

Therapeutic Applications

Tadalafil is used to treat high blood pressure in the lungs (pulmonary hypertension). It works by relaxing and widening the blood vessels in your lungs which allows the blood to flow more easily. Decreasing high blood pressure in the lungs allows your heart and lungs to work better and improves your ability to exercise.

Tamsulosin Hcl

Generic Formulation: Tamsulosin HclSpecialty: Urology
Provider Metrics Summary
Total Claims 81
30-Day Fills 215.6
Days Supply 6,468
LA State Average Benchmarks
Peer Average Claims96.0
Peer Average 30-Day Fills196.8
Peer Average Days Supply5,816
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,447.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.87

State Avg Cost Per Claim

$14.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tamsulosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Tamsulosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. STEPHEN F. BARDOT MD provides transparency into local medical care patterns within New Orleans, LA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Urology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.